5h
Zacks Investment Research on MSNChemours, NTT DATA & Hibiya Engineering Join Forces for Product TrialThe Chemours Company CC recently announced the launch of a full-scale product trial with NTT DATA and a leading regional ...
Chemours (NYSE:CC) is preparing to appoint the chief executive of Vision One Management Partners to its board in an effort to ...
Chemours, a global leader in delivering innovative performance chemistry, today announced the launch of a full-scale product trial with NTT DATA and a leading regional engineering firm, Hibiya ...
Chemours Co. plans to add the chief executive officer of Vision One Management Partners to its board as it seeks to avoid a ...
It is unclear what actions the Trump administration will take, if any, to protect the public against PFAS, linked to cancer and other health problems.
Chemours joins forces with NTT DATA and Hibiya Engineering, Ltd. to advance data center two-phase immersion cooling with ...
Company announced the launch of a full-scale product trial with NTT Data and a regional engineering firm, Hibiya Engineering, ...
The Chemours Company (NYSE:CC) shareholders might understandably be very concerned that the share price has dropped 33% in the last quarter. On the bright side the share price is up over the last half ...
North Carolina ordered Chemours to expand PFAS well testing, adding 150,000 homes in six counties, including Harnett and Hoke ...
The N.C. Department of Environmental Quality is continuing Chemours’ search for groundwater contamination beyond the Lower ...
Zacks Research cut their Q1 2025 earnings per share (EPS) estimates for Chemours in a research note issued to investors on ...
Barclays analyst Michael Leithead maintained a Hold rating on Chemours Company (CC – Research Report) today and set a price target of $19.00.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results